Navigation Links
Misonix Announces Change in Distribution of SonaStar® Surgical Aspiration System in the U.S.
Date:10/12/2010

FARMINGDALE, N.Y., Oct. 12 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced a definitive agreement to end its non-exclusive distribution arrangement in the United States with Aesculap, Inc. for the SonaStar® Surgical Aspiration System.  

As a result, Misonix will assume exclusive responsibility for the marketing, sales, distribution and service of the SonaStar effective October 18, 2010, utilizing its previously established 75 person sales and service organization, which began direct to hospital marketing of the SonaStar late last year.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

"We are very excited about bringing all domestic sales of SonaStar under our focused sales organization," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Over time, we expect to gain significant margin improvement and sales growth by enabling our proprietary sales organization to sell another one of our key products exclusively under the Misonix label."

About Misonix:Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.Investor Relations Contact:Kevin McGrath / Cameron Associates, Inc.212-245-4577Kevin@cameronassoc.com
'/>"/>

SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results
2. Misonix Schedules Fourth Quarter and Fiscal 2010 Financial Results Conference Call; September 28, 2010 at 4:30 p.m. Eastern
3. Misonix Announces New Distribution Agreement For Spain
4. Misonix Announces New Distribution Agreement for France
5. Misonix Announces New Distribution Agreement for Russia
6. Misonix Announces New GPO Agreement With First Choice Cooperative
7. Misonix Announces New Distribution Agreement for Mexico
8. Misonix Announces New Distribution Agreement for Peru
9. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
10. Misonix Reports First Quarter Fiscal 2010 Financial Results
11. Misonix Announces New Distribution Agreement for Argentina
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 /PRNewswire/ ... University of Alberta in Edmonton, Canada ... partner journal, Schizophrenia 1 , demonstrating that AI ... schizophrenia with 74% accuracy. This retrospective analysis also ... symptoms in schizophrenia patients with significant correlation, based ...
(Date:7/21/2017)... 21, 2017  Endo International plc (NASDAQ: ... review of its manufacturing network, the Company will be ... in Huntsville, Alabama . The closure ... the next 12 to 18 months. The ... volumes of commoditized products and these restructuring actions are ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... , ... “Now Hiring!” is a popular phrase at Home Delivery Incontinent ... sales for over 30 consecutive years and now plans to hire more than 100 ... excitement and growth at HDIS, following the company’s acquisition by Fortune 1000 company Domtar. ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... the launch of their partnership to provide the Pharmacist eCare Plan ... platform in the country with the ability to develop the Pharmacist eCare Plan, ...
(Date:7/25/2017)... Spring Arbor, Mich. (PRWEB) , ... July 25, ... ... director of special education programs at Spring Arbor University recently co-authored and published ... of Self-Determination in Adolescents with Neonatal Brachial Plexus Palsy. Both the article and ...
(Date:7/25/2017)... ... 25, 2017 , ... Facing medical needs with a newborn boy this spring, ... a new benefit for employees that is uncommon in American business: 12 weeks of ... me and other employees as new parents. It keeps our family life more stable. ...
(Date:7/24/2017)... ... 24, 2017 , ... Engineers at the University of Maryland have invented an ... of electrical energy that the body uses. , In ordinary batteries the electrical ... electrons out of the battery is generated by moving positive ions from one end ...
Breaking Medicine News(10 mins):